BIO

ANALYST NOTE: BIO (Bio-Rad Laboratories, Inc.) Date: 2026-06-13 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

Current State: Forming Entry Parameters:

Volatility Context: Current ATR is 3.4%, categorized as "productive" within the StoryStocks canon (sub-threshold <2.5% is weak; 4–6% is the historical sweet spot). This suggests sufficient volatility to support a move, though not yet at the "high" volatility sweet spot typically seen at confirmed breakouts.

• Conservative Entry: Not yet available (requires confirmed breakout).
• Aggressive Entry: $280.38 (Pre-breakout / forming entry).
• Breakout Level: $343.12 (Resistance level that must be cleared to confirm the setup).

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Macro Context: There is NO named secular thesis or macro theme attached to this name as of 2026-06-13. The investment case is strictly driven by the quality of the technical setup (the forming coil) and the underlying business fundamentals. Judgment Criteria: Conviction must be derived solely from the structural integrity of the base, the durability of the business model, and the management's guidance. Do not invent a macro narrative; judge the setup on its own merits.

3. Business Overview

Company Profile: Bio-Rad Laboratories, Inc. is a multinational developer, manufacturer, and worldwide distributor of life science research and clinical diagnostics products. The company operates with a diverse client base including scientific research, healthcare, education, and government customers. Segments & Revenue Mix:

Geographic Exposure: Approximately 39% of 2026 consolidated net sales are derived from the United States, while 61% are derived from international locations, with Europe being the largest international region. Product & Market Dynamics:

• Life Science Segment: Develops, manufactures, and markets instruments, systems, reagents, and consumables for separating, purifying, and characterizing biological materials. This segment generated approximately 40% of consolidated net sales for the year ended December 31, 2025.
• Clinical Diagnostics Segment: Designs, manufactures, and supports diagnostic test systems, informatics solutions, and quality controls for clinical laboratories. This segment generated approximately 60% of consolidated net sales for the year ended December 31, 2025.
• The company sells over 12,000 products and services.
• Revenue is characterized by recurring nature due to customer requirements for standardization in experiments and test results.
• Digital PCR Growth: As of the April 2026 earnings call, the team has enabled over 99% of digital PCR assays to be available on the new QX700 series, which is currently driving instrument growth.
• Market Size: Management estimates the worldwide sales of products in the markets served to be approximately $16 billion to $19 billion (based on varying estimates in filings).

4. Archetype and Conviction Stack

Archetype: Quality Compounder Rationale: The business fits the "Quality Compounder" archetype due to its recurring revenue model, high barrier to entry in specialized diagnostics, and durable end markets (Life Science and Diagnostics). Management explicitly stated that while end markets are "challenged in the near term," they are "durable and resilient." Fundamental Context (Management Expectations):

Conviction Stack:

• Revenue Guidance: Management expects currency-neutral revenue growth for the full year 2026 to be between -3% and +0.5%. This reflects a period of contraction or stagnation, primarily driven by regional conflicts in the Middle East and currency headwinds.
• Margin Profile: Despite lower revenue, management projects full-year non-GAAP gross margins between 53% and 54%, noting that lower revenue reduces fixed cost absorption and higher freight rates are offsetting factors. Operating margins are projected between 10% and 12%.
• Cash Flow: Free cash flow is estimated in the range of $290 million to $340 million for 2026.
• Balance Sheet: The company holds $400 million and $800 million in Senior Notes maturing in March 2027 and March 2032, respectively, with interest rates of 3.3% and 3.7%.
• Strategic Asset: As of December 31, 2025, Bio-Rad owned approximately 38% of the outstanding ordinary shares of Sartorius, representing a significant strategic equity stake.
• Thesis Strength: Low (No macro tailwinds; purely tactical).
• Evidence Quality: High (Recent earnings transcript and SEC filings provide clear guidance and operational data).
• Rerating Potential: Dependent on the resolution of the "challenged" near-term conditions and the successful rollout of the QX700 series. The current setup suggests the market is pricing in the near-term headwinds, and a breakout would signal a re-rating based on the durability of the business model.

5. Invalidations, Strengths, and Gaps

Invalidation Conditions:

• Fundamental: A significant deterioration in the "durable and resilient" thesis, such as a failure of the QX700 series adoption or a widening of the revenue decline beyond the -3% guidance.

Strengthening Conditions:

• Technical: A confirmed close above $343.12 (Breakout Level).
• Fundamental: Evidence that the "challenged" end markets are stabilizing faster than the -3% to +0.5% guidance implies, or a successful monetization of the Sartorius stake.

Evidence Gaps:

• Missing Evidence: There is no specific data provided regarding the *timing* of the recovery from the Middle East conflict impact beyond the statement that "conditions [are expected] to continue through the rest of 2026."
• Missing Evidence: No specific data on the *rate* of QX700 instrument adoption beyond the "99% assay availability" metric.
• Missing Evidence: No specific guidance on the *impact* of the Sartorius equity stake on 2026 earnings beyond the ownership percentage.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: Revenue guidance of -3% to +0.5% indicates near-term contraction; Regional conflicts in the Middle East expected to persist through 2026; Breakout level of $343.12 is significantly distant from current price ($282.44). Sizing hint: Position size should reflect the "forming" nature of the setup; treat as a partial conviction play rather than a confirmed breakout trade. Expected path: Management expects revenue to remain flat-to-down through 2026 with stable margins; the setup implies the market is pricing in this stagnation, and a move higher requires a catalyst that shifts sentiment from "challenged" to "resilient." Expected horizon: 3 to 6 months for the setup to resolve (either breakout or invalidation). Failure mode to watch: A daily close below $260.58, which would confirm the "challenged" thesis is playing out in the price action and invalidate the base.